关于严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）刺突突变 T478K 的初步报告。
Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K.
机构信息
Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
出版信息
J Med Virol. 2021 Sep;93(9):5638-5643. doi: 10.1002/jmv.27062. Epub 2021 May 15.
Abstract
Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have emerged, posing a renewed threat to coronavirus disease 2019 containment and to vaccine and drug efficacy. In this study, we analyzed more than 1,000,000 SARS-CoV-2 genomic sequences deposited up to April 27, 2021, on the GISAID public repository, and identified a novel T478K mutation located on the SARS-CoV-2 Spike protein. The mutation is structurally located in the region of interaction with human receptor ACE2 and was detected in 11,435 distinct cases. We show that T478K has appeared and risen in frequency since January 2021, predominantly in Mexico and the United States, but we could also detect it in several European countries.
摘要
已经出现了几种严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）变体，这对 2019 年冠状病毒病的控制以及疫苗和药物的疗效构成了新的威胁。在这项研究中，我们分析了截至 2021 年 4 月 27 日在 GISAID 公共存储库中存储的超过 100 万个 SARS-CoV-2 基因组序列，并在 SARS-CoV-2 刺突蛋白上鉴定出一种新型 T478K 突变。该突变在结构上位于与人类受体 ACE2 的相互作用区域，在 11435 个不同病例中被检测到。我们表明，自 2021 年 1 月以来，T478K 已经出现并增加了频率，主要在墨西哥和美国，但我们也可以在几个欧洲国家检测到它。
相似文献
1
Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K.
J Med Virol. 2021 Sep;93(9):5638-5643. doi: 10.1002/jmv.27062. Epub 2021 May 15.
2
Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021.
Infect Genet Evol. 2022 Jan;97:105164. doi: 10.1016/j.meegid.2021.105164. Epub 2021 Nov 27.
3
Emergence and spread of the potential variant of interest (VOI) B.1.1.519 of SARS-CoV-2 predominantly present in Mexico.
Arch Virol. 2021 Nov;166(11):3173-3177. doi: 10.1007/s00705-021-05208-6. Epub 2021 Aug 27.
4
V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
J Virol. 2021 Jul 26;95(16):e0061721. doi: 10.1128/JVI.00617-21.
5
Genomic variance of Open Reading Frames (ORFs) and Spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
J Chin Med Assoc. 2020 Aug;83(8):725-732. doi: 10.1097/JCMA.0000000000000387.
6
Uncovering the impact of SARS-CoV2 spike protein variants on human receptors: A molecular dynamics docking and simulation approach.
J Infect Public Health. 2023 Oct;16(10):1544-1555. doi: 10.1016/j.jiph.2023.07.011. Epub 2023 Jul 24.
7
Longitudinal analysis of SARS-CoV-2 spike and RNA-dependent RNA polymerase protein sequences reveals the emergence and geographic distribution of diverse mutations.
Infect Genet Evol. 2022 Jan;97:105153. doi: 10.1016/j.meegid.2021.105153. Epub 2021 Nov 18.
8
Detection of R.1 lineage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with spike protein W152L/E484K/G769V mutations in Japan.
PLoS Pathog. 2021 Jun 7;17(6):e1009619. doi: 10.1371/journal.ppat.1009619. eCollection 2021 Jun.
9
Dynamics of SARS-CoV-2 variants of concern (VOC) in Bangladesh during the first half of 2021.
Virology. 2022 Jan 2;565:29-37. doi: 10.1016/j.virol.2021.10.005. Epub 2021 Oct 22.
10
SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021.
Microbiol Spectr. 2021 Dec 22;9(3):e0109621. doi: 10.1128/Spectrum.01096-21. Epub 2021 Nov 17.
引用本文的文献
1
Structural impact of synonymous mutations in six SARS-CoV-2 Variants of Concern.
PLoS One. 2025 Jul 1;20(7):e0325858. doi: 10.1371/journal.pone.0325858. eCollection 2025.
2
Comparison of the pathogenicity of multiple SARS-CoV-2 variants in mouse models.
Animal Model Exp Med. 2025 Jul;8(7):1302-1312. doi: 10.1002/ame2.70029. Epub 2025 May 20.
3
Broadly potent spike-specific human monoclonal antibodies inhibit SARS-CoV-2 Omicron sub-lineages.
Commun Biol. 2024 Oct 2;7(1):1239. doi: 10.1038/s42003-024-06951-7.
4
COVID-19 mutations: An overview.
World J Methodol. 2024 Sep 20;14(3):89761. doi: 10.5662/wjm.v14.i3.89761.
5
Detection and Characterisation of SARS-CoV-2 in Eastern Province of Zambia: A Retrospective Genomic Surveillance Study.
Int J Mol Sci. 2024 Jun 7;25(12):6338. doi: 10.3390/ijms25126338.
6
Most accurate mutations in SARS-CoV-2 genomes identified in Uzbek patients show novel amino acid changes.
Front Med (Lausanne). 2024 May 31;11:1401655. doi: 10.3389/fmed.2024.1401655. eCollection 2024.
7
Biophysical principles predict fitness of SARS-CoV-2 variants.
Proc Natl Acad Sci U S A. 2024 Jun 4;121(23):e2314518121. doi: 10.1073/pnas.2314518121. Epub 2024 May 31.
8
Mutational dynamics of SARS-CoV-2: Impact on future COVID-19 vaccine strategies.
Heliyon. 2024 Apr 25;10(9):e30208. doi: 10.1016/j.heliyon.2024.e30208. eCollection 2024 May 15.
9
Current molecular diagnostics assays for SARS-CoV-2 and emerging variants.
Methods Microbiol. 2022;50:83-121. doi: 10.1016/bs.mim.2021.10.003. Epub 2021 Dec 9.
10
Within-host evolution of SARS-CoV-2: how often are mutations transmitted from symptomatic infections?
Virus Evol. 2024 Feb 21;10(1):veae006. doi: 10.1093/ve/veae006. eCollection 2024.
本文引用的文献
1
E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies.
J Mol Graph Model. 2021 Dec;109:108035. doi: 10.1016/j.jmgm.2021.108035. Epub 2021 Sep 17.
2
Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.
Immunity. 2021 Aug 10;54(8):1853-1868.e7. doi: 10.1016/j.immuni.2021.07.008. Epub 2021 Jul 30.
3
Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: An insight from structural data.
J Cell Physiol. 2021 Oct;236(10):7045-7057. doi: 10.1002/jcp.30367. Epub 2021 Mar 23.
4
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
N Engl J Med. 2021 May 20;384(20):1885-1898. doi: 10.1056/NEJMoa2102214. Epub 2021 Mar 16.
5
Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity.
Biochem Biophys Res Commun. 2021 Jan 29;538:97-103. doi: 10.1016/j.bbrc.2021.01.035. Epub 2021 Feb 15.
6
Structural genetics of circulating variants affecting the SARS-CoV-2 spike/human ACE2 complex.
J Biomol Struct Dyn. 2022 Sep;40(14):6545-6555. doi: 10.1080/07391102.2021.1886175. Epub 2021 Feb 13.
7
SARS-CoV-2 variants and ending the COVID-19 pandemic.
Lancet. 2021 Mar 13;397(10278):952-954. doi: 10.1016/S0140-6736(21)00370-6. Epub 2021 Feb 11.
8
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.
Nat Med. 2021 Apr;27(4):620-621. doi: 10.1038/s41591-021-01270-4. Epub 2021 Feb 8.
9
SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity.
Nat Commun. 2021 Feb 8;12(1):848. doi: 10.1038/s41467-021-21118-2.
10
Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January 12, 2021.
MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70(3):95-99. doi: 10.15585/mmwr.mm7003e2.
Zotero 插件